Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HVTN 305: sD-NP-GT8 and IL-12 DNA HIV Vaccine
NCT05781542Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2023
- Primary completion
- Oct 2024
- Countries
- 2
01
Overview
Phase 1, open-label trial of sD-NP-GT8 DNA in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Apr 2023; status: completed.
02
Drugs
sD-NP-GT8 DNA
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05781542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05781542.